ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced that the Group has obtained an investigational new drug (IND) approval for IMM47 for the treatment of solid tumors from the National Medical Products Administration of the People's Republic of China (NMPA).
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Equities
1541
CNE100006624
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.26 HKD | +0.71% | -2.46% | -52.31% |
06-03 | ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug | MT |
05-30 | ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares | MT |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-52.31% | 679M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- 1541 Stock
- News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China